An independent review entitled “Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer” is published on March 30th, 2020 in Molecular Diagnosis and Therapy (Blair, H.A. Mol Diagn Ther (2020)[1] a specialized journal of Springer Nature group that provides researchers and healthcare professionals with insights into the latest molecular diagnostic and therapeutic techniques and their use in precision medicine https://doi.org/10.1007/s40291-020-00459-6).
Immunoscore® is an in vitro diagnostic assay informing the physician about the patient’s immune response on the tumour site. It is provided by HalioDx (https://www.haliodx.com/) and is available to the patients in several countries.
Read more about the review here.
Learn more at the COLOSSUS website at www.colossusproject.eu. View the COLOSSUS explainer video here. Follow the project on Twitter @COLOSSUSEU.
COLOSSUS has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 754923. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.